Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I really don't care if GC files or not.
It not why we are here.
But based on all the information and communications,
its not ethical to file late at this Juncture.
The CEO should become the Marketing Director, and step down.
What kind of None-sense is this CEO?
I know some of you love him,
but I"m voting him off the island.
Buy Buy Buy AMBS Money Train Leaving soon
GRANT ABSTRACT
Objective/Rationale:
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
Project Description:
We will first optimize the MANF-derived peptide in vitro to find out its minimal size, effective concentration and to exclude the adverse effects on the healthy cells. The optimized peptide will then be tested on the 6-hydroxydopamine (6-OHDA) neuroprotection model of Parkinson’s disease. The peptide or Glial Cell Line-Derived Neurotrophic Factor (GDNF) as a positive control will be injected to the striata of the models, followed by 6-OHDA injection 6 h later. 2 and 4 weeks later the amphetamine-induced rotational behavior of the models will be tested to reveal the extent of the functional damage of the dopaminergic system. At the end of the experiment, the brain sections will be stained with the tyrosine hydroxylase antibodies to reveal the extent of the histological damage of the dopaminergic system.
Relevance to Diagnosis/Treatment of Parkinson’s Disease:
As the small-size peptide spreads better in the brain parenchyma than the larger proteins, it should be more efficient than the full-length MANF protein. Also, as MANF can efficiently prevent cell death intracellularly, the cell-penetrating properties of the MANF-derived peptide could attenuate its neurotrophic efficiency.
Anticipated Outcome:
A short, lay-oriented description of what you expect to learn by carrying out the work. Approximately 75 words
We expect that the MANF-derived peptide confers significant protection against 6-OHDA-induced symptoms of Parkinson’s disease. In particular, the reduction in the amphetamine-induced rotation and in the loss of dopaminergic neurons and fibers is expected. If so, future studies include spreading of the peptide in the brain and its neurorestorative potency when applied after the 6-OHDA.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=927
MANF corrected the neurological deficits when it was given immediately after the animals became sick. MANF also corrected the neurological deficits when it was given three weeks after the models became sick. This means that MANF is able to prevent the death of healthy dopaminergic neurons, but also MANF can save dopaminergic neurons that are already dying. How do these results apply to human patients? The results suggest that in patients newly diagnosed with Parkinson's disease MANF might be able to save those dopaminergic neurons that are sick and dying, but not yet dead. These patients will likely get better sooner, and their recovery will also last for a longer time. It is much too soon to predict whether MANF will be able to cure Parkinson's disease. MANF is certainly one of the most promising molecules currently in development to treat this debilitating disease.
Yes I know this is old news for you multiple million share holders,
this is for the shareholders newer to the board.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=644
OH Great CEO where art thou 10-k for AMBS
Hey, not to rain on your parade but filing late is
the worst thing you can do as a CEO.
Excellent post, can we place on top of list by owners of board?
This new research is worth $1.00 per share
http://seekingalpha.com/article/2132133-still-several-reasons-to-remain-long-amarantus
http://www.genecards.org/cgi-bin/carddisp.pl?gene=MANF
MANF & Diabetes
8K dated 6/3/11
Amarantus enters into a Letter Agreement regarding Intellectual Properties Licensing and Collaboration Arrangements with Generex Biotechnology Corporation.
In addition to receiving a license of the Generex Technologies, they also agreed to collaborate with Generex regarding research and development of MANF and related molecules, as well asm the PhenoGuard process for application in the field of diabetes treatment.
----------------------------------------------
Press Release dated 6/8/11
"The joint efforts of many players, starting from the discovery of a new use of MANF at UMass Medical School for diabetes, and the synergies of two highly committed organizations, has allowed us to generate a unique opportunity to launch a commercial development program for MANF as a biomarker of cellular stress and stressed beta cells in diabetes," said Dr. Fumihiko Urano, associate professor at the University of Massachusetts Medical School, who identified MANF's role in this area.
Concurrently with this announcement, Amarantus announced that it has executed an Exclusive Option Agreement with the University of Massachusetts Medical School ("UMMS") to license intellectual property recently developed at UMMS to advance Amarantus' diabetes diagnostic development and commercialization program using Amarantus' lead protein MANF as a biomarker for beta cell stress.
----------------------------------------------
8K dated 7/25/11
On June 3, 2011, we disclosed entering into a Letter Agreement (the “Agreement”) with Generex Biotechnology Corporation (“Generex”) regarding the licensing of certain intellectual properties and forming collaborative arrangements for the benefit of the parties. In our disclosure, we explained that the material terms of the Agreement will be evidenced by further documentation to be delivered on a formal Closing Date to take place no later than July 15, 2011.
Although we are still in negotiations with Generex over the material terms and are actively pursuing developing the necessary documentation to close the transaction, we have not been able to do so by our target date of July 15, 2011.
----------------------------------------------
Press Release dated 8/4/11
The potential of Amarantus' proprietary PhenoGuard cell immortalization process to create a stable source of representative beta cells that can be used in cell replacement therapy in patients who have lost virtually all beta cell function represents a potential major breakthrough for the treatment of chronic, late-stage diabetes," said Dr. James Anderson, Senior Scientific Advisor and Director of Generex
The two companies are currently planning to develop a MANF-based diagnostic test to identify a sub-population at risk of developing Type 1 or Type 2 diabetes
"To date, the Amarantus PhenoGuard technologies have been able to immortalize cells in a manner that maintains the phenotypic characteristics of the cells being immortalized," said Dr. John Commissiong, Chief Scientific Officer of Amarantus. "The potential to create immortal clones of beta cells that could be used in cell therapy procedures would further validate the Amarantus technologies, positioning Amarantus as a unique resource for novel cell lines, while creating a powerful tool to change the clinical outcomes in patients with the most severe forms of diabetes."
----------------------------------------------
July 2012
The company became aware of the escalation of a patent dispute, in the form of a formal hearing with the European Union brought forth by Hermo Pharma (Mart Saarma), based in Helsinki, Finland. Hermo had sought to invalidate the Company’s European composition of matter patents based upon what the Company believed to be frivolous grounds.
At a hearing held November 6, 2012 the Opposition Division of the European Patent Office upheld the Company’s European Patents relating to neurotrophic factor MANF, following opposition by rival Hermo.
----------------------------------------------
8K dated 10/17/12
On 17 October 2012, Amarantus BioSciences, Inc. was awarded a Translational Research Grant award from the University of Massachusetts' Pioneer Valley Life Sciences Institute's Center of Excellence in Apoptosis Research (CEAR). With award of the Grant, Amarantus agreed to collaborate with the University of Massachusetts to conduct a study to exploit publicly available genomics databases to identify potentially new therapeutic targets for Mesencdphalic Astrocyte derived Neurotrophic Factor, or MANF-based therapeutics, and then validate those hypotheses in cell-based laboratory research, which could lead to the identification and patenting of therapeutic indications for MANF beyond what has already been reported. MANF is a protein that corrects protein misfolding, one of the major causes of Apoptosis, or cell death.
----------------------------------------------
Press Release dated 10/17/12
"The literature on MANF has grown extensively during the past few years, and there appears to be a solid rationale for investigating the potential use of MANF in areas other than Parkinson's disease," said Dr. Lawrence M. Schwartz, Isenberg Professor of Integrative Sciences at the University of Massachusetts and current Amarantus Scientific Advisor who will serve as the Principal Investigator on the project. "Our study compliments the work of other labs around the world that are focusing on MANF. Our relationship with Amarantus will be critical to ensure that we can translate this basic science into clinical research in a number of different therapeutic indications."
"This grant will enable Amarantus to explore the full breadth of the MANF opportunity," said Gerald E. Commissiong, President & CEO of Amarantus. "As our development program for Parkinson's progresses towards the critical milestone of identifying the best delivery target(s) for MANF, identifying additional disease targets for MANF therapy could significantly increase the value of our intellectual property portfolio and make Amarantus more attractive to potential partners."
----------------------------------------------
8K dated 04/01/13
On March 26, 2013, the Company and Generex Biotechnology Corporation entered into an agreement of termination and release terminating the letter agreement between them dated May 30, 2011. A copy of the Agreement of Termination and Release is filed herewith as Exhibit 10.1.
AGREEMENT OF TERMINATION AND RELEASE, made this 26th day of March 2013 (the “Agreement”), by and between Amarantus BioSciences, Inc. (“Amarantus”) and Generex Biotechnology Corporation (“Generex”). Amarantus and Generex collectively shall be referred to as the “Parties.”
WHEREAS, the Parties hereto entered into a Letter Agreement dated as of May 30, 2011 (the “Letter Agreement”), which, among other things, contains certain rights, obligations, and duties of the Parties; and
WHEREAS, the Parties desire to mutually terminate the Letter Agreement;
WHEREAS, each of the Parties desires to release each of the other Parties from any and all claims in connection with or relating to the Letter Agreement;
----------------------------------------------
Patent Filing 01/23/13
Patent: Soluble manf in pancreatic beta-cell disorders
Inventors: Fumihiko Urano
Applicant: University of Massachusetts
----------------------------------------------
Article dated 8/7/2013
Professor Mart Saarmareceives $ 495 000 for diabetes research
The Juvenile Diabetes Research Foundation (JDRF) has awarded a research grant of $ 495 000 for three years for supporting a collaborative team headed by Professor Mart Saarma at the Institute of Biotechnology, University of Helsinki and Professor Timo Otonkoski at Biomedicum Stem Cell Center. The aim of the project is to study therapeutic potential of neurotrophic factor MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor) in preclinical research for type 1 diabetes. The therapeutic effect of MANF will be studied using rodent and human pancreatic islets, b -cell lines and in rodent models of diabetes.
Professor Mart Saarma's team is currently studying the structure, biology and therapeutic potential of neurotrophic factors GDNF, CDNF and MANF for neurodegenerative diseases. The indication for neurotrophic factor MANF to be a candidate therapeutic factor for diabetes came from Dr. Maria Lindahl´s work (Saarma group, Institute of Biotechnology). These studies showed that Manf-deficient mice were diabetic due to progressive loss of insulin-producing pancreatic b -cells. The team in the collaborative project includes top experts in the fields of endocrinology, neurosciences and genetic engineering of mice.One of the main goals in type 1 diabetes therapy is to define a method for functional b -cell proliferation and regeneration.
"We have found that MANF can protect and stimulate proliferation of b -cells in a mouse model of type 1 diabetes. In addition, we generated mice which lack MANF protein, resulting in development of T1D. Since MANF has direct effects of mouse b -cells and is expressed and regulated in human b - cells we hope that MANF has therapeutic potential for the treatment of T1D, where b -cell protecting and regenerating therapies are not available" says Professor Mart Saarma.
----------------------------------------------
Email From Dr. Urano 12/5/13
"We believe that our research on MANF will lead to a novel treatment for Wolfram and other neurodegenerative diseases."
----------------------------------------------
GC Tweet 4/8/14
@MainePerks: is $NVS tinkering with MANF?
@G_Commish: I cannot discuss, sorry. Thanks for your interest.
AMBS
Is MANF to become the "Holy Grail" of the medical community in the coming decade and beyond? Great Find Knack!! Mart Saarma has been busy spending that 500K on his research with resounding results. "MANF Is Indispensable for the Proliferation and Survival of Pancreatic ß CellsMANF Is Indispensable for the Proliferation and Survival of Pancreatic ß Cells.[color=red][/color] Additionally, we show that lack of MANF in vivo in mouse leads to chronic unfolded protein response (UPR) activation in pancreatic islets. Importantly, MANF protein enhanced ß cell proliferation in vitro and overexpression of MANF in the pancreas of diabetic mice enhanced ß cell regeneration. We demonstrate that MANF specifically promotes ß cell proliferation and survival, thereby constituting a therapeutic candidate for ß cell protection and regeneration."
Research continues to reveal the amazing healing power of MANF that bridges the species. The more research that is done, the more dramatic is the evidence. MANF is going to be revolutionary in medicine in our lifetimes it would appear! Wow, what an article!
Is PHOT UP IN SMOKE? Oh we'll buy low sell high, whoops no pun intended
Come'on, join the Fantastic Voyage, Money Train
Can we get a "Refresh" of the IHub AMBS Web Page. Newer investors are coming and they should have the latest information.
I think a Medical MJNA type Division would
super charge AMBS ability to trade higher,
get more financing at decent rates, and bring in much
needed cash flow. Its 100Billion market, so what is wrong with Legal MJNA business plan added to the highly diluted shell
he has assembled. I fully believe in the Science possibilities,
with MANF and Elt, Lym, etc. They all have excellent possibilities.
But today with Medical MJNA on board, it could easily be added to the company since it is a holding company and have a separate operating division, the stock would fly. It would be AMBS on Steroids. But if not, we have a nice pipeline to hold onto.
But there are fast selling business models and slow ones.
I"m telling mgt, get into MJNA business,
and 800million shares will not matter.
otherwise live a life of sub dollar worlds.
Get on the Train ride, The Fantastic Voyage
Money Train The Fantastic Voyage
"Fantastic Voyage" is a 1980 funk single by Dayton, Ohio-based group, Lakeside. The song hit number one on the R&B chart and was the group's only entry on the Billboard Hot 100, where it peaked at number fifty-five.[1]
Medical Marijuana Program - Lets have a AMBS Division,
http://www.cdph.ca.gov/programs/MMP/Pages/default.aspx
It would not take much money, a couple million?
They could really juice up their finances with that business plan,
added as a wholly owned subsidiary.
I will vote for this.
Why not have a MJNA Division?
Get on the Money Train.
It would make sense to spin-off Lympro to shareholders.
Create a separate public entity and "payback" current investors with some value. While using the Highly diluted holding company to create
the public spin-off entities.
" We have found that MANF can protect and stimulate proliferation of b -cells in a mouse model of type 1 diabetes. In addition, we generated mice which lack MANF protein, resulting in development of T1D. Since MANF has direct effects of mouse b -cells and is expressed and regulated in human b - cells we hope that MANF has therapeutic potential for the treatment of T1D, where b -cell protecting and regenerating therapies are not available" says Professor Mart Saarma.
AMBS. " We have found that MANF can protect and stimulate proliferation of b -cells in a mouse model of type 1 diabetes. In addition, we generated mice which lack MANF protein, resulting in development of T1D. Since MANF has direct effects of mouse b -cells and is expressed and regulated in human b - cells we hope that MANF has therapeutic potential for the treatment of T1D, where b -cell protecting and regenerating therapies are not available" says Professor Mart Saarma.
What is MANF Thursday, January 16, 2014
Begin Quote
"MANF, Wolfram, and Diabetes: What is MANF? Why did the biotech license my invention?
Since a biotech company in California licensed my invention on MANF for therapeutics and diagnostics for Wolfram syndrome and Type 1 diabetes, I have been getting a lot of emails on this topic. I would like to briefly explain you about MANF. In short, MANF is one of our targets for developing patient-based therapeutics and diagnostics for Wolfram syndrome and type 1 diabetes.
MANF stands for mesencephalic astrocyte-derived neurotrophic factor. This molecule is created in our body, and it was originally isolated from a type of brain cells called astrocytes. Several years ago, we discovered that MANF was secreted from pancreatic beta cells and neurons when their endoplasmic reticulum calcium was depleted. We thought that this was a potential biomarker for Wolfram syndrome and filed an invention disclosure. Interestingly, we found several articles reporting that MANF can confer protection against neuronal cell death mediated by endoplasmic reticulum dysfunction. So we started testing if MANF might confer protection against pancreatic beta cell death mediated by ER dysfunction, and the preliminary results were positive.
We still have to do a lot of preclinical studies. Also, the company that has licensed our invention is mainly developing drugs for Parkinson's disease. However, it is good news that they are also interested in Wolfram syndrome and type 1 diabetes." End Quote
Reference: http://wolframsyndrome.blogspot.com/2014/01/manf-wolfram-and-diabetes-what-is-manf.html
Important Development and Collaborations
I believe we should have three components for the treatment of Wolfram syndrome.
1. Delay the progression of the disease with existing FDA-approved drugs.
This is our current major focus, and we have a rising candidate. We are looking for a simple way to assess the efficacy of this drug in patients and are trying to collect blood samples from patients and their siblings. In parallel, we are also looking for a new group of drugs that can delay the progression of the disease with a company. All of these drugs seem to be related to cellular calcium homeostasis.
2. Enhance the viability of eye cells, brain cells, and pancreatic beta cells.
In Wolfram syndrome, brain cells, eye cells, and beta cells in the pancreas are sensitive to cell stress and susceptible to cell death due to the mutations in the WFS1 gene. We are developing a method to make brain cells, eye cells, and pancreatic beta cells, more resistant to cell stress. We have identified an interesting hormone-like molecule produced in our body called MANF. MANF can make our cells more resistant to cell stress-mediated cell death. We are trying to establish a collaboration with a pharmaceutical company to develop a drug based on our findings.
3. Replace damaged tissues using patients' skin cells.
As I mentioned in my previous blogs, we have created induced pluripotent stem cells (iPS cells) using skin cells from patients. We are creating brain cells and eye cells using these iPS cells. These cells have been useful to dissect out the mechanisms of the disease and test the efficacy of candidate drugs. We are also replacing a pathogenic WFS1 gene part with a healthy WFS1 gene part in these cells. In the future, we will use these cells for replacing damaged tissues.
Reference:
http://wolframsyndrome.blogspot.com/2014/03/important-development-and-collaborations.html
So if we get a status update on MANF and b - cells, and we have a large Pharma to engage AMBS at this point, or just the research. How much is that worth? Well I would think the shares would trade in the 1Billion market cap area for starters, we are at 45million now.
So what about 20 times higher or .80 or .90 cents. Under a buck. But if a large pharma indicated to support co-development marketing, it would push it much much higher. Aug Last year:
" We have found that MANF can protect and stimulate proliferation of b -cells in a mouse model of type 1 diabetes. In addition, we generated mice which lack MANF protein, resulting in development of T1D. Since MANF has direct effects of mouse b -cells and is expressed and regulated in human b - cells we hope that MANF has therapeutic potential for the treatment of T1D, where b -cell protecting and regenerating therapies are not available" says Professor Mart Saarma.
update due in April Approx., Back ground of that letter of yours Zoomboom
MANF-JDRF --Professor Mart Saarma receives $ 495,000 for diabetes research (August 7, 2013)
The Juvenile Diabetes Research Foundation (JDRF) has awarded a research grant of $ 495 000 for three years for supporting a collaborative team headed by Professor Mart Saarma at the Institute of Biotechnology, University of Helsinki and Professor Timo Otonkoski at Biomedicum Stem Cell Center. The aim of the project is to study therapeutic potential of neurotrophic factor MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor) in preclinical research for type 1 diabetes. The therapeutic effect of MANF will be studied using rodent and human pancreatic islets, b -cell lines and in rodent models of diabetes.
Professor Mart Saarma's team is currently studying the structure, biology and therapeutic potential of neurotrophic factors GDNF, CDNF and MANF for neurodegenerative diseases. The indication for neurotrophic factor MANF to be a candidate therapeutic factor for diabetes came from Dr. Maria Lindahl´s work (Saarma group, Institute of Biotechnology). These studies showed that Manf-deficient mice were diabetic due to progressive loss of insulin-producing pancreatic b -cells. The team in the collaborative project includes top experts in the fields of endocrinology, neurosciences and genetic engineering of mice.
Prof. Timo Otonkoski is a pediatrics endocrinologist whose research topic for many years has been in the development and renewal of insulin-producing pancreatic b -cells. Dr. Maria Lindahl´s research has focused on the role of neurotrophic factors in the endocrine system by developing and analysing several genetically modified mice models. Dr. Jari Rossi (Institute of Biomedicine) has extensive experience in genetically engineered mice, and studying energy balance and metabolism. Doctoral students M.Sc. Tatiana Danilova and MD Erik Palm will be tightly involved in the project by working on cell lines, rodent islets and mouse models. MD Elina Hakonen will focus on human islets and cell lines.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D.
One of the main goals in type 1 diabetes therapy is to define a method for functional b -cell proliferation and regeneration.
" We have found that MANF can protect and stimulate proliferation of b -cells in a mouse model of type 1 diabetes. In addition, we generated mice which lack MANF protein, resulting in development of T1D. Since MANF has direct effects of mouse b -cells and is expressed and regulated in human b - cells we hope that MANF has therapeutic potential for the treatment of T1D, where b -cell protecting and regenerating therapies are not available" says Professor Mart Saarma.
You mean CYTR CytRx on Nasdaq?
You are saying that AMBS would buy CYTR?
http://www.ncbi.nlm.nih.gov/pubmed/23741470
http://www.cytrx.com/bafetinib
i will buy 500k shares more here
Yes for sure at 50 million market cap now we should be at 500million
market cap or say .90 cents
\
so yes this is a steal
Correct christjamin, market cap going to 500,000,000 500 million. then to 5,000,000,000,000 5 billion
at 500 million we are at .90 cents approx.
at 5 Billion we are at 9 bucks approx.
SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until he co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradable detergent and the 10 second Polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
"Clearly, Dr. Rubinfeld joining the Advisory Board is a tremendous endorsement for the Company at this critical juncture in our growth cycle," said Gerald E. Commissiong, President & CEO of Amarantus. "The Advisory Board is now well populated with extremely talented experts in the various fields that are necessary to position us for growth: science, investment banking/M&A, business development and regulatory affairs. We now intend to leverage these relationships to fill out the management team and Board of Directors with development expertise and Big Pharma experience in order to attract the capital necessary to advance our development programs towards key value inflexion milestones."
Dr. Rubinfeld is the fourth member of Amarantus' Advisory Board.
The good Doctor was in the right place at right time
$AMBS - Advisor Joseph Rubinfeld - Founder AMGN
http://www.veracast.com/bio/ceoinvestor2014/main/events/1393_amaran/pdf/Amarantus_BioScience.pdf
dsw, Joseph Rubinfield Co-Founder of AMGN, Inc., Very nice presentation you have uncovered: see attached link
http://www.veracast.com/bio/ceoinvestor2014/main/events/1393_amaran/pdf/Amarantus_BioScience.pdf
For AMEX in this case, $2.00 needed in stock price.
Up-Listing to AMEX for example see link
http://www.amex.com/equities/howToLst/Eq_HTL_ListStandards.html
• Quest Diagnostics is the world’s leading provider of diagnostic information services
• Generated 2013 revenues of approximately $7.1 billion
• Publicly trades common stock on the New York Stock Exchange (NYSE: DGX). More in Investor Relations
• Ranks as a component of the Standard & Poor's 500
• Touches the lives of 30 percent of American adults each year
• Serves about half of the physicians and hospitals in the U.S
• Engages workforce of about 41,000 employees dedicated to putting patients first every day
• Operates more than 2,200 patient service centers
• A medical and scientific staff of more than 700 M.D.s and Ph.D.s Strong logistics capabilities, including approximately 3,000 courier vehicles and 20 aircraft that collectively make tens of thousands of stops daily
• Offers physicians a test menu that is industry leading in breadth and innovation. Our test menu ranges from routine biological tests to complex and specialized molecular and gene-based testing as well as anatomic pathology
• Provides broad range of solutions for employers, including workplace drug testing for employers and government agencies; the BluePrint for Wellness employee wellness service; and risk assessment services for the life insurance industry
• Publishes original research in peer reviewed publications, at medical and scientific conferences, and as a public service. Quest Diagnostics Health Trends reports examine trends in diseases based on the company’s United States database. Quest Diagnostics Drug Testing Index (DTI) reports examine trends in workplace drug testing, and have been considered a benchmark for U.S. workforce drug positivity trends since 1988
Laboratory and Office Locations Around the World
Quest Diagnostics has headquarters in the U.S. and operations in India, Ireland, Mexico, and the United Kingdom. Our products and services are used by customers in over 130 countries. We also collaborate with many international diagnostic laboratories, hospitals and clinics to help improve human health around the world.
United States
We offer broad access to clinical testing services through our national network of laboratories in most major metropolitan areas as well as approximately 2,000 patient locations. Make an appointment at a patient location. Read more about our products and services.
India
Through our state-of-the-art laboratory facility in Gurgaon, we provide a range of products and services to physicians, hospitals, life insurance companies and pharmaceutical/biotech companies in India.
Ireland
In 2006, the Ireland national health administration engaged with us to help reduce a critical backlog of Pap-based cervical cancer screening tests. Since then, Quest Diagnostics has helped to improve the delivery of timely results for patients and expanded its service offering in Ireland.
Mexico
With two central labs accredited by the College of American Pathologists (CAP) and approximately 35 patient locations, Quest Diagnostics Mexico is one of the preeminent private clinical laboratories in Mexico City and Ciudad Juarez. We offer domestic and international testing services, including clinical trials, drug screening, life insurance assessments and specialized, complex testing. More about our business in Mexico (in Spanish).
United Kingdom
We are one of the largest independent diagnostic service providers. Our main facility, located near Heathrow airport, offers a comprehensive testing menu that services the clinical trials industry. We work with both private and public laboratories. Read more
Clinical Trials - In-house and Affiliate Laboratory Management
We operate in-house laboratories in the United States and United Kingdom, complemented by alliance laboratories in Australia, China, Singapore, and South America. Read more
Patient Locations
Choose from approximately 2,000 patient locations across the U.S. Find a location convenient for you – you can even make an appointment.
Licenses & Accreditations
Read more about our CLIA (Clinical Laboratory Improvement Amendments) licenses and CAP (College of American Pathologists) accreditation. CAP programs are aligned with international standards.
Lab Contact Info
Looking for an address or phone number for a laboratory facility? Click here.
Headquarters
Our corporate headquarters are in New Jersey, about 30 miles west of New York City. Administrative offices are also in Lyndhurst, NJ and Collegeville, PA (near Philadelphia).
3 Giralda Farms
Madison, NJ 07940
1-800-222-0446
http://www.questdiagnostics.com/home/about/locations.html
Becton Dickinson
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. BD is headquartered in the United States and has offices in more than 50 countries worldwide.
BD is a medical technology company that serves healthcare institutions, life science, researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.
The BD Veritor™ System is a Digital Immunoassay (DIA), a new category of testing, that allows you to analyze all that you see, and all that you can't.
BD DIAGNOSTICS
BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems to accurately detect a broad range of infectious diseases, healthcare-associated infections (HAIs) and cancers. The BD Diagnostics segment focuses on improving health outcomes for patients by providing laboratories with solutions that improve quality, enhance laboratory system productivity and inform medical decisions.
PRODUCTS/SERVICES
• Integrated systems for specimen collection
• Safety-engineered blood collection products and systems
• Automated blood culturing systems
• Molecular testing systems for infectious diseases and women's health
• Microorganism identification and drug susceptibility systems
• Liquid-based cytology systems for cervical cancer screening
• Rapid diagnostic assays
• Plated media
• Microbiology laboratory automation
CUSTOMERS SERVED
• Hospitals, laboratories and clinics
• Reference laboratories
• Blood banks
• Healthcare workers
• Public health agencies
• Physicians’ office practices
• Industrial and food microbiology laboratories
http://www.bd.com/aboutbd/wwbusinesses/diagnostics.asp
Yes, that's only $3.00 for one times sales of LymPro.
With all things considered its a $50 stock.
Buy it, ship it, close your Ihub account.
Open up a browser in three years. You'll be happy.
Or for you non-math types, $3.00 per share at current market cap.
I think its 1.6billion sales per year potential
What is Upper Sales Limit on LymPro,
Lymphocyte Proliferation test ("LymPro Test®")
Anyone know the number, sales that is.